lixudebart

all catalysts(1)

News(3)

• Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
  The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medi…
  biopharma_dive · 5d ago
• CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
  CSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune diseas…
  biospace · 5d ago
• CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
  Australia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.
  fiercebiotech · 6d ago